Please login to the form below

Not currently logged in
Email:
Password:

J&J's profit falls as sales increase

Johnson & Johnson’s third quarter profit for 2011 has fallen 6.3 per cent despite an increase in the US-based pharmaceutical company’s sales performance

Johnson & Johnson's (J&J) third quarter profit for 2011 has fallen 6.3 per cent, with net earnings $3.20bn during the period compared to $3.42bn in 2010.

The dip in profit performance contrasted with the company's sales, which increased by 6.8 per cent to $16.01bn.

However, both the cost of products sold and expenses related to selling, marketing and administration increased significantly between 2010 and 2011 for J&J, with the company also affected by a higher tax rate.

William C Weldon, chairman and CEO of J&J, described the company's performance as “solid” and commended the effect recent product launches have had on revenue.

Regionally, US pharmaceutical sales declined 6.1 per cent, while international sales increased 27.5 per cent to $3.11bn, overtaking the company's revenue in the US.

Sales results in the US were negatively impacted by generic competition for Levaquin (levofloxacin), a treatment for bacterial infections.

A webcast is available concerning J&J's financial results for the third quarter of 2011.

19th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...

Infographics